Anticoagulation for Patients with Atrial Fibrillation in Ambulatory Care Settings

References

1. ↵
   Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999; 30: 1991–4.

   OpenUrlFREE Full Text
2. ↵
   Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 162–82.

   OpenUrl
3. ↵
   Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002; 106: 388–91.

   OpenUrlFREE Full Text
4. ↵
   Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 429S–56S.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Public use data file documentation: 2004 National Ambulatory Medical Care Survey. Hyattsville (MD): National Center for Health Statistics; 2006.
6. ↵
   International classification of diseases, ninth revision, clinical modification. 6^th ed. Washington, DC: Public Health Service; 1998.
7. ↵
   Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231–3.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004; 164: 55–60.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003; 41: 56–61.

   OpenUrlPubMedWeb of Science
10. ↵
    Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577–617.

    OpenUrlAbstract/FREE Full Text
11. ↵
    Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes. Stroke 2005; 36: 374–87.

    OpenUrlAbstract/FREE Full Text
12. ↵
    Christian JB, Lapane KL, Toppa RS. Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents. Stroke 2003; 34: 2693–7.

    OpenUrlAbstract/FREE Full Text
13. ↵
    Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008; 25: 151–9.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Williams JE, Chimowitz MI, Cotsonis GA, Lynn MJ, Waddy SP; WASID Investigators. Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis. Stroke 2007; 38: 2055–62.

    OpenUrlAbstract/FREE Full Text
15. ↵
    Mahmud A, Bennett K, Okechukwu I, Feely J. National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol 2007; 64: 575–7.

    OpenUrlPubMed
16. ↵
    Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study. BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503.

    OpenUrl
17. ↵
    Srivastava A, Hudson M, Hamoud I, Cavalcante J, Pai C, Kaatz S. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J 2008; 6: 6.

    OpenUrlCrossRefPubMed
18. ↵
    Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med 1996; 156: 1841–8.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000; 320: 1380–4.

    OpenUrlAbstract/FREE Full Text
20. ↵
    Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003; 25: 1750–64.

    OpenUrlCrossRefPubMedWeb of Science